During the past 12 months, Integrated Diagnostics Holdings's average EPS without NRIGrowth Rate was -34.10% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -23.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -5.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 11.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 12 years, Integrated Diagnostics Holdings's highest 3-Year average EPS without NRI Growth Rate was 47.60% per year. The lowest was -23.60% per year. And the median was 13.90% per year.
Integrated Diagnostics Holdings EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Integrated Diagnostics Holdings's EPS (Diluted)
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings's PE Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's PE Ratio distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Integrated Diagnostics Holdings EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IDGXF has been successfully added to your 